* If you want to update the article please login/register
After FFX's failure, this report investigates the effectiveness and safety of adding Nab-paclitaxel to Gem for mPA. Methods In this retrospective real-world multicenter study, from 2011 to 2020, patients with mPA receiving Gem-Nab or Gem alone were included after progression on FFX. Patients on Gem-Nab had more metastatic sites, peritoneal disease, and lower PS 2 than those receiving placebos. Conclusion Conclusions: Gem-Nab was shown to have higher DCR, PFS, and OS in patients with mPA after FFX failure, although in patients with higher toxicity, despite higher risk of increased toxicity.
Source link: https://europepmc.org/article/MED/35094032
Background In 80% of patients with metastatic pancreatic duct carcinoma adenocarcinoma, the new therapy, consisting of at least doublet-chemotherapy for fit patients, pain symptoms in the upper abdomen and back are common. Stereotactic body radiation therapy can produce high radiation doses in a few fractions, thereby reducing chemotherapy-free intervals. However, prospective evidence on pain relief after SBRT of pPCa is very limited. In a prospective trial, we intend to investigate the effects of SBRT on pain management in patients with mPDAC. Methods This is a prospective, double-arm, randomized controlled, international multicenter research examining the added value of MR-guided adaptive SBRT of the pPca embedded between the pPca and standard care-chemotherapy cycles for pain control and prevention of pain in patients with mPDAC. In three centers in Germany and Switzerland, 82 patients with histologically confirmed mPDAC and at least stable disease after the first 8 weeks of SoC-CT will be eligible for the trial and 1:1 randomized as part of SoC-CT's first eight weeks, or control arm A, which continues SoC-CT without SBRT. Discussion An unmet medical need is a long-term monitoring of pain in patients with mPDAC. Patients with mPDAC will be aided by a local treatment of the pPCa by MR-guided SBRT in terms of a durable pain control system with a simultaneously favorable safe toxicity profile, resulting in an improvement in quality-of-life. We suspect that patients with mPDAC may benefit from a mPDAC-guided SBRT's characterization of a durable pain control with a durable pain control with a high positive safe toxicity profile, a.
Source link: https://europepmc.org/article/MED/35078490
Palliative radiotherapy is a medical treatment of mPDAC, and is often used for pain relief in the treatment of mPDAC. The real-world effect of radiotherapy on the survival of mPDAC patients is well-known and is worth investigating. PDAC patients with liver metastasis resuming and recovery were able to improve overall survival, but not for PDAC patients with lung, bone, and brain metastasis prior to PSM. In the cox regression study, radiotherapy can only be a prognostic factor for PDAC liver metastasis. With and without lung, bone, and/or brain metastasis, we continue to divide PDAC liver patients into PDAC-liver-metastasis. Finally, radiotherapy can be used as a cost-effective therapy to prolong the overall survival of patients with PDAC liver metastasis without the presence of LBB metastasis. Conclusions: Radiotherapy can be used as a cost-effective therapy to prolong the overall survival of patients with PDAC liver metastasis without LBB metastasis.
Source link: https://europepmc.org/article/MED/35069888
Sarcina ventriculi is a rare gram-positive coccus that has been delayed gastric emptying or gastric outlet obstruction, and it is often associated with emphysematous gastritis and perforation. This is the first reported case of Sarcina ventriculi in an FNA of metastatic pancreatic carcinoma in a perigastric lymph node, according to our knowledge.
Source link: https://europepmc.org/article/MED/35003818
BACKGROUND Web-paclitaxel/gemcitabine/FOLFIRINOX are two promising drugs in metastatic pancreatic cancer. This review reviewed a novel first-line sequential therapy in MPC that may have the ability to prevent primary therapy resistance and slow tumor progression. Patients and methods Patients with histologically/cytologically confirmed MPC were included in a multicentric trial that included AG and FFX, followed by FFX. In phase Ib, three dose-levels were tested for maximum tolerated dose and suggested phase II dose. In phase Ib, we included 33 patients of median age 61. 0 years and 58% males, with 34 percent being represented by 54. 8% males. We included 58 patients of median age 60 years, 50% males, and with Eastern Cooperative Oncology Group stage scores 0 and 1 of 37. 9% and 61%, respectively, in phase II. In 61. 4% of patients, tumor response was complete in 3. 5 percent and partial, while disease was stable in 19. 3% and progressive in 15. 8%.
Source link: https://europepmc.org/article/MED/34837745
BACKGROUND The actual study of patients with metastatic pancreatic duct carcinoma adenocarcinoma is limited to single centers, limiting the generalizability of their findings. In a broader context, this research sought to find key population-based predictors of survival in patients with mPDAC. Methods Data between 1 January 2017 and 31 December 2019 were extracted from the Flatiron Health EHR website. Patients treated with first-line gemcitabine+nab-paclitaxel, FOLFIRINOX, gemcitabine monotherapy, and two-line liposomal irinotecan-based regimens were provided with treatment-specific predictive models. Patients undergoing particular medications differed from the overall scheme, GNP, FOLFIRINOX, and gem-mono. For patients treated with second-line liposomal irinotecan, both Alkaline phosphatase, SA, and WBC counts were important predictors of survival. Conclusions in this real-world study of patients with mPDAC found in a large population of patients undergoing systemic therapy, indicating important prognostic factors of survival.
Source link: https://europepmc.org/article/MED/34811961
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions